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Background: The measurement of platelet reactivity in patients with stroke un-
dergoing antiplatelet therapies is not commonly performed in clinical practice.
We assessed the prevalence of therapy responsiveness in patients with stroke and
further investigated differences between patients on prevention therapy at stroke
onset and patients naive to antiplatelet medications. We also sought differences
in responsiveness between etiological subtypes and correlations between Clopidogrel
responsiveness and genetic polymorphisms. Methods: A total of 624 stroke pa-
tients on antiplatelet therapy were included. Two different groups were identified:
“non-naive patients”, and “naive patients.” Platelet function was measured with
multiple electrode aggregometry, and genotyping assays were used to determine
CYP2C19 polymorphisms. Results: Aspirin (ASA) responsiveness was signifi-
cantly more frequent in naive patients compared with non-naive patients (94.9%
versus 82.6%, P < .0010). A better responsiveness to ASA compared with Clopidogrel
or combination therapy was found in the entire population (P < .0010), in non-
naive patients (P < .0253), and in naive patients (P < .0010). Multivariate analysis
revealed a strong effect of Clopidogrel as a possible “risk factor” for unrespon-
siveness (odds ratio 3.652, P < .0001). No difference between etiological subgroups
and no correlations between responsiveness and CYP2C19 polymorphisms were
found. Conclusion: In our opinion, platelet function testing could be potentially
useful in monitoring the biological effect of antiplatelet agents. A substantial pro-
portion of patients with stroke on ASA were “resistant,” and the treatment with
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Clopidogrel was accompanied by even higher rates of unresponsiveness. Longi-
tudinal studies are needed to assess whether aggregometry might supply
individualized prognostic information and whether it can be considered a valid
tool for future prevention strategies. Key Words: Stroke, ischemic—stroke
prevention—platelet inhibitor—secondary prevention—aggregometry.
© 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Introduction
Control of cerebrovascular risk factors and therapeu-
tic secondary prevention are fundamental to prevent
ischemic cerebrovascular events (transient ischemic attack
[TIA]/stroke). Treatment of noncardiogenic strokes (ath-
erosclerotic, lacunar, or cryptogenic infarcts) is based on
antiplatelet agents, which reduce the relative risk of stroke
or death on average by about 22%.1,2 Regarding their mech-
anism of action, antiplatelet agents are classified in 3
groups: thromboxane inhibitors (Aspirin [ASA], ASA-
dipyridamole), ADP receptor antagonists (thienopyridines:
Clopidogrel, Ticlopidine), and glycoprotein IIb/IIIa in-
hibitors. Oral antiplatelet therapy, with ASA, ASA-
dipyridamole, and thienopyridines, showing similar
effectiveness,3 is strongly recommended in secondary stroke
prevention.4,5 The treatment of recurrences remains less
clear; it is mandatory to exclude alternative causes of stroke
and to improve control of risk factors, but no clear guide-
lines for alternative therapeutic strategies are available.
In everyday clinical practice, after recurrence of isch-
emic stroke, a therapeutic shift to another antiplatelet agent
is the most common option, although there is no evi-
dence based on clinical trials indicating that this is
associated with a reduction of the risk of recurrence.
In recent years, the clinical response variability to ASA
or Clopidogrel treatment and the phenomenon of “low”
or “nonresponsiveness,” “antiplatelet resistance,” or “high
on-treatment platelet reactivity” (HTPR), defined as bio-
chemical failure of the antiplatelet agent to inhibit tests
of platelet function ex vivo, have been widely explored.6,7
The mechanisms for resistance might include an insuf-
ficient dose, poor compliance, related gene polymorphisms,
baseline platelet hyperactivity, and accelerated platelet
turnover.8,9
Different methods of platelet function testing are avail-
able to assess inhibition of function induced by antiplatelet
agents: light transmission aggregometry, the gold stan-
dard for monitoring antiplatelet effects ex vivo, but with
difficult routine application; vasodilator-stimulated phos-
phoprotein assay, specific for evaluation of Clopidogrel
responsiveness; Impact-R cone and platelet analyzer; Plate-
let Function Assay-100; and VerifyNow Ultegra RPFA. A
fairly new generation of impedance aggregometer, named
multiple electrode platelet aggregometry (MEA; Multiplate,
Roche Diagnostics International Ltd, Rotkreutz,
Switzerland),10,11 showed correlations with the estimates
of Clopidogrel and ASA antiplatelet effect obtained by
other methods.12
A greater risk of recurrence of cardiovascular events
has been demonstrated in patients with resistance to ASA
or Clopidogrel.13-17 Furthermore, pharmacological inter-
actions with other drugs (e.g., proton-pump inhibitor) have
been associated with a diminished pharmacodynamic re-
sponse to Clopidogrel.18 Recently, a systematic review and
meta-analysis of randomized clinical trials was per-
formed to evaluate the clinical efficacy and safety of
intensified antiplatelet therapy versus Clopidogrel at a
standard dosage, on the basis of platelet reactivity testing,
in patients undergoing percutaneous coronary interven-
tion who presented HTPR.19 The intensified therapy
protocol was associated with a significant reduction in
cardiovascular mortality, stent thrombosis, and myocar-
dial infarction, with no difference in the rate of major
bleeding between the 2 groups, although the net clini-
cal benefit significantly depended on the risk of stent
thrombosis with standard Clopidogrel dose. Similarly,
another systematic review and meta-analysis on random-
ized trials, concerning tailored antiplatelet therapy in
antiplatelet-resistant patients, showed a minor occur-
rence of death or clinical adverse events in personalized
antiplatelet therapy compared with conventional treatment.20
Although several data are available on cardiovascular
diseases, there are a small number of studies regarding
monitoring of antiplatelet therapy in patients with isch-
emic stroke. In most of them, the evaluation of antiplatelet
effect has been performed mainly with Platelet Func-
tion Assay-100, with evidence of a low responsiveness
to low-dose or enteric-coated ASA in a significant pro-
portion of patients (37%) in Alberts et al’s study.21 Other
data pointed to limitations of platelet aggregation moni-
toring, particularly in terms of reliability of results.22-24
The Trinity Antiplatelet Responsiveness study investi-
gated the prevalence of ex vivo nonresponsiveness in
patients with ischemic stroke/patients with TIA evalu-
ated with a “longitudinal definition of HTPR” by
comparing responsiveness to antiplatelet therapy at follow-
up with patients’ baseline values.25 Payne et al reported
a significant clinical impact of monitoring the intake of
a single dose of Clopidogrel with flow cytometry and
aggregometry before carotid endarterectomy to reduce post-
operative embolization.26 Recently, some studies evaluated
the prevalence of antiplatelet responsiveness by using MEA
in a cerebrovascular setting; Meves et al reported HTPR
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to Clopidogrel therapy in 44% of 159 patients with isch-
emic stroke, and besides time-dependency of the antiplatelet
effect, major risk factors reported for resistance were di-
abetes mellitus and higher HbA1c values.27 Nevertheless,
other evidence advises against a platelet function-
guided modification of antiplatelet therapy after an ischemic
stroke or TIA: Depta et al reported an association between
increase of therapeutic dosages and rate of adverse clin-
ical outcome, without differences in terms of ischemic
events.28 A more recent 2-phase pilot study assessed the
reproducibility of results on ASA responsiveness using
MEA between healthy volunteers, naive to ASA, and pa-
tients with acute ischemic stroke or TIA. Results
demonstrated that the Multiplate device could feasibly
supply reproducible and precise results in both groups,
encouraging its implementation in routine clinical practice.29
In conclusion, although several studies support its im-
plementation, the routine measurement of platelet reactivity
in patients with ischemic stroke has not been incorpo-
rated in clinical practice, mainly due to a lack of consensus
on the optimal methods to use and of consistent data
on the effective improvement of clinical outcome with
tailored therapy. The aim of the current observational study
was to assess the prevalence of antiplatelet therapy re-
sponsiveness in a large Italian acute stroke population,
and to determine potential differences in responsive-
ness between patients already on antiplatelet secondary
prevention therapy at stroke onset and patients who were
naive to antiplatelet medications before the ischemic event.
On the background of recent findings regarding the in-
dividual differences in Clopidogrel absorption and
metabolization, we also studied genetic polymorphisms
within the CYP2C19 gene in our patients with stroke:
CYP2C19*2 (c.681G>A; Single Nucleotide Polymor-
phism ID number rs4244285) and CYP2C19*17 (c.806C>T;
rs12248560) allelic variants. Clopidogrel is a prodrug that
requires conversion into an active metabolite by hepatic
cytochrome P450 isoenzymes, in a 2-step sequential
bioactivation. Many studies indicate that the isoenzyme
CYP2C19 contributes to both of the oxidative steps re-
quired for conversion.30,31 Hypotheses suggest that the
variability of responsiveness to Clopidogrel, with absent
or insufficient active metabolite generation, might be pri-
marily due to limited intestinal absorption or to functional
variability in P450 isoenzyme activity. Some studies have
evaluated therefore the influence of polymorphisms of
gene encoding CYP2C19 isoenzymes.32-35 Two common
and functionally relevant polymorphisms exist within the
CYP2C19 gene: CPY2C19*2(*2), resulting in complete loss
of CYP2C19 enzyme activity, and CYP2C19*17(*17), re-
sulting in increased enzyme function. Although the loss-
of-function (LoF) allele confers a higher risk of adverse
events by affecting the pharmacodynamics response to
Clopidogrel, no single study has clearly demonstrated a
link between the presence of LoF genetic polymor-
phism, decreased Clopidogrel responsiveness, and adverse
clinical outcome. On the background of these findings,
we additionally evaluated potential correlations between
responsiveness and CYP2C19 genotype in a group of
Clopidogrel patients of the study population.
Materials and Methods
Study Design
In this observational study, we assessed the preva-
lence of antiplatelet therapy responsiveness, using
impedance aggregometry, in a population of 624 pa-
tients with acute stroke treated with a standard dose of
ASA (100 mg/day), Clopidogrel (75 mg/day), or with a
combination of both drugs. In this sample, we further
identified 2 different groups: patients who were already
on antiplatelet treatment at the time of stroke onset (called
“non-naive patients”) and patients who started
antithrombotic therapy because of the ischemic stroke that
led to hospitalization (called “naive patients”). The plate-
let function was tested within a mean interval of 24-48
hours from admission in the former group, and a mean
interval of 7-10 days after treatment initiation in the latter
group. To avoid potential confounding effects, we ex-
cluded patients whose previous antiplatelet therapy was
shifted to another antiplatelet medication because of the
cerebrovascular event (e.g., shift from ASA to Clopidogrel
during hospitalization). Associations between patients’ clin-
ical characteristics and responsiveness to antiplatelet therapy
were sought. We further compared the responsiveness to
antiplatelet therapy with the different antiplatelet medi-
cations (ASA, Clopidogrel, or a combination of both drugs)
in the entire study population and in the 2 different groups.
In non-naive patients, we also assessed the preva-
lence of antiplatelet responsiveness within etiological
subgroups of patients, identified on the basis of the un-
derlying mechanism of the current ischemic event (large
artery atherosclerosis, small artery disease, cardiogenic
embolism, undetermined etiology, other determined causes).
Each patient, therefore, underwent an extensive diag-
nostic workup to identify the correct etiopathogenetic
mechanism of the index event.
We finally evaluated responsiveness among the
Clopidogrel patients of the study population in whom
we were able to assess the CYP2C19 genotype (*1/*1, *1/
*17, *17/*17, *2/*17, *2/*2, *1/*2).
Impedance Aggregometry
Platelet function in whole blood was measured by using
Multiple Electrode Aggregometry on a Multiplate Ana-
lyzer® (Roche Diagnostics International Ltd CH-6343
Rotkreutz, Switzerland).36,37 Description of the imped-
ance aggregometry system and of cut-off values for
responsiveness are reported in Method I in the online-
only Supplementary data.
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CYP2C19*2 and CYP2C19*17 Genotyping
Specific single nucleotide polymorphism (SNP)
Genotyping TaqMan assays (C_25986767_70 and
C_469857_10, Life Technologies, Grand Island, NY) were
used for the detection of rs4244285 and rs12248560, re-
spectively (“DMGA CYP2C19*2”, rs4244285, assay ID
C_25986767_70; “DMGA CYP2C19*17”, rs12248560, assay
ID C_469857_10). Description of SNP Genotyping TaqMan
assays system is shown in Method II in the online-only
Supplementary data.
Statistical Analysis
Descriptive statistical analyses, assessing the percent-
age of patients on ASA, Clopidogrel, or ASA plus
Clopidogrel therapy, were performed in the entire pop-
ulation and in each of the study groups. Chi-square or
Fisher exact tests were used to compare proportions
between groups. Possible associations between antiplatelet
therapy unresponsiveness and demographic and clini-
cal factors were examined using stepwise logistic regression.
Unadjusted and adjusted odds ratio (OR) and the cor-
responding P values were calculated for each variable
included in the univariate and multivariate models. P < .05
was considered statistically significant. All calculations
were conducted using SAS Enterprise Guide version 5.1
(SAS Institute Inc., Cary, NC).
Results
Clinical and Demographic Characteristics of Patients
This observational study analyzed 624 consecutive pa-
tients with acute ischemic stroke referred to our stroke
unit. Two different groups were identified: non-naive pa-
tients, including 278 patients who were already treated
with antiplatelet therapy at stroke onset (219 patients were
treated with ASA, 33 patients with Clopidogrel, and 26
patients with a combination of both [ASA plus
Clopidogrel]), and naive patients, including 346 pa-
tients who started antiplatelet therapy because of the
ischemic event (196 patients started ASA, 89 patients
Clopidogrel, and 61 patients ASA plus Clopidogrel). De-
mographic and clinical characteristics of patients are
reported in Table 1, A. The group of patients who were
already on antiplatelet secondary prevention therapy at
stroke onset (non-naive patients) were significantly older
(P < .0001); the frequencies of hypertension (P = .0001), pre-
vious cerebrovascular or myocardial ischemic events
(P < .0001), relevant carotid stenosis (P = .0165), smoking
(P = .0148), hyperlipidaemia and hyperhomocysteinemia
(P = .0040 and P = .0344, respectively), and patency of the
foramen ovale (P = .0012) were significantly higher in this
group. In addition, the use of ASA was significantly more
frequent in non-naive patients (P < .0001), whereas
Clopidogrel or dual antiplatelet therapies were signifi-
cantly more frequent among naive patients (P < .0001 and
P = .0030, respectively). The etiological subgroups iden-
tified among the study population are reported in Table 1,
B. Large artery atherosclerosis and cardiogenic embo-
lism subgroups were significantly more frequent in the
first study group (non-naive patients) (P = .0309 and
P < .0001, respectively), whereas lacunar strokes and strokes
of undetermined etiology were more frequent among naive
patients (P = .0016 and P = .0048, respectively). In a smaller
group of patients treated with Clopidogrel or with a com-
bination of ASA and Clopidogrel, we were able to study
the genetic polymorphisms within the CYP2C19 gene. The
expressed genotypes assigned to each patient in the entire
population and in the 2 study groups are shown in Table 1,
C. There were no statistical differences between study
groups considering CYP2C19*2 and CYP2C19*17 geno-
types, except for the CPY2C19*1(*2) allelic variant being
slightly more frequent among non-naive patients.
Prevalence of Antiplatelet Therapy Responsiveness in
the Study Population
Based on platelet aggregation testing, 122 patients (19.6%)
were determined to be nonresponders in the entire study
population, considering all antiplatelet medications. Fifty-
six patients (20.1%) were nonresponders in the first group
(non-naive patients) and 66 patients (19.1%) in the second
group (naive patients). There were no significant differ-
ences between the 2 groups by chi-square testing (P= .7379).
When considering ASA therapy, in the entire popula-
tion, 48 patients (11.6%) were nonresponders: 38 patients
(17.4%) among non-naive patients and 10 patients (5.1%)
among naive patients. There was a significantly larger
prevalence of therapy responsiveness in the second group
(patients who started ASA treatment during hospitaliza-
tion) by chi-square testing (P < .0010). When considering
Clopidogrel therapy, 44 patients (36.1%) of the entire pop-
ulation were determined to be nonresponders: 9 patients
(27.3%) were nonresponders among non-naive patients,
35 patients (39.3%) among naive patients, and there were
no significant differences between the 2 groups by chi-
square testing (P = .2181). In the entire population on
combination therapy with ASA and Clopidogrel, 30 pa-
tients (34.5%) were determined to be nonresponders to
both of them. Nine patients (34.6%) were nonresponders
among non-naive patients, and 21 patients (34.4%) among
naive patients. No significant differences between the 2
groups by chi-square testing were found (P = .9864).
Measures of Association between Clinical
Characteristics and Antiplatelet Therapy
Unresponsiveness
The entire study population was examined to deter-
mine if there was any association between antiplatelet
therapy unresponsiveness and demographic and clini-
cal characteristics reported in Table 1, A; the univariate
analysis revealed that the severity of stroke (onset National
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Institute of Health Stroke Scale) and the residual disabil-
ity (discharge National Institute of Health Stroke Scale)
slightly increased the odds of being nonresponsive to
antiplatelet therapy, but multivariate logistic regression
analysis did not confirm these associations. With regard
to the other tested variables, univariate analysis re-
vealed that nonresponders were more frequently reported
under Clopidogrel (OR = 2.89, P < .0001) and dual
Table 1. (A) Demographic and clinical characteristics of study population, (B) etiological subgroups in study population, and (C)







(N = 624) P value
Variable
Age (SD) 72.1 (11.5) 65.9 (15.1) 68.6 (13.9) <.0001
Male (%) 185 (66.5) 215 (62.1) 400 (64.1) .2539
Onset NIHSS (±SD) 6.7 (±7.1) 6.4 (±6.7) 6.5 (±6.8) .6449
Discharge NIHSS (±SD) 3.6 (±5.8) 2.9 (±5.4) 3.2 (±5.6) .1217
Hypertension (%) 236 (84.9) 249 (72) 485 (77.7) .0001
Previous stroke (%) 63 (22.7) 30 (8.7) 93 (14.9) <.0001
Previous TIA (%) 31 (11.2) 21 (6.1) 52 (8.3) .0224
ICA stenosis >50% (%) 115 (41.4) 111 (32.1) 226 (36.2) .0165
Atrial fibrillation (%) 61 (21.9) 24 (6.9) 85 (13.6) <.0001
Diabetes mellitus (%) 76 (27.3) 72 (20.8) 148 (23.7) .0567
Prior myocardial infarction (%) 90 (32.4) 34 (9.8) 124 (19.9) <.0001
Cigarette smoking (%) 72 (25.9) 121 (35.0) 193 (30.9) .0148
Hyperlipidemia (%) 214 (77) 230 (66.5) 444 (71.2) .0040
Hyperhomocysteinemia (%) 51 (18.3) 88 (22.3) 139 (22.3) .0344
History of neoplasia (%) 20 (7.2) 30 (8.7) 50 (8.0) .4996
Obesity (%) 36 (12.9) 40 (11.6) 76 (12.2) .5980
Foramen ovale patency 8 (2.9) 32 (9.2) 40 (6.4) .0012
ASA 219 (78.8) 196 (56.6) 415 (66.5) <.0001
Clopidogrel 33 (11.9) 89 (25.7) 122 (19.6) <.0001
ASA plus Clopidogrel (ASA + C) 26 (9.3) 61 (17.6) 87 (13.9) .0030
(B)
Large artery atherosclerosis (%) 90 (32.4) 85 (24.6) 175 (28) .0309
Small artery disease (%) 40 (14.4) 85 (24.6) 125 (20) .0016
Cardiogenic embolism (%) 70 (25.2) 36 (10.4) 106 (17) <.0001
Undetermined etiology (%) 61 (21.9) 111 (32.1) 172 (27.6) .0048
Other causes (%) 14 (5.0) 26 (7.5) 40 (6.4) .2090




C = 21, ASA + C = 17
Naive patients
(n = 92)
C = 54, ASA + C = 38
Total
(N = 130) P value
CPY2C19*1(*1) 11 (28.9) 40 (43.5) 51 (39.2) .1228
CPY2C19*1(*17) 10 (26.3) 28 (30.5) 38 (29.2) .6386
CPY2C19*1(*2) 11 (28.9) 13 (14.2) 24 (18.5) .0477
CPY2C19*17(*17) 2 (5.3) 4 (4.3) 6 (4.6) .7623
CPY2C19*2(*17) 3 (7.8) 4 (4.3) 7 (5.4) .4162
CPY2C19*2(*2) 1 (2.8) 3 (3.2) 4 (3.1) .7540
Abbreviations: ICA, internal carotid artery; NIHSS, National Institute of Health Stroke Scale; SD, standard deviation; TIA, transient isch-
emic attack.
Continuous variables are indicated as mean ± SD and categorical variables as frequencies and percentages.
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antiplatelet therapy (OR = 2.96, P = .0002). Further mul-
tivariate logistic regression analysis, including the variable
“study group” as an independent factor, confirmed this
association: the odds of being nonresponders was in-
creased by 3.65-fold with Clopidogrel therapy (P < .0001)
and by 3.60-fold with dual antiplatelet therapy (P < .0001).
Overall results are summarized in Table 2.
Comparison between Responsiveness to Different
Antiplatelet Medications (ASA, Clopidogrel, or ASA
Plus Clopidogrel) in the Study Population and in the 2
Groups
In the entire study population, there was a significant
difference in responsiveness to the different antiplatelet
therapies; in particular, patients had a better responsive-
ness to ASA therapy compared with Clopidogrel or
combination therapy by chi-square testing (P < .0010) (Fig 1,
A). In the group of patients who was already on antiplatelet
treatment at the time of the acute stroke (non-naive pa-
tients), there was a significant difference in responsiveness
to the different antiplatelet therapies; in particular, patients
had a better responsiveness to ASA therapy compared
with Clopidogrel or combination therapy by chi-square
testing (P = .0253) (Fig 1, B). In the group of patients who
started antithrombotic therapy following the ischemic stroke
(naive patients), the prevalence of responsiveness was,
again, significantly different among different types of
antiplatelet agents; in particular, patients had a better re-
sponsiveness to ASA compared with Clopidogrel or
combination therapy by chi-square testing (P < .0010) (Fig 1,
C).
Prevalence of Responsiveness within Etiological
Subgroups in Non-Naive Patients
Prevalence of antiplatelet responsiveness to all medi-
cations and to ASA, Clopidogrel, ASA plus Clopidogrel
separately, in each etiological subgroup of patients, is shown
in Table I in the online-only Supplementary data. There
were no significant differences in the proportion of
nonresponders across etiological subgroups considering
all antiplatelet medications, Clopidogrel, or dual antiplatelet
therapy by chi-square testing (P = .2509, P = .7281, P = .3360,
respectively). A significant difference was found consid-
ering ASA therapy (P = .0479): in this group of patients
(N = 219) the prevalence of ASA responsiveness was 90%,
74%, and 86% in large artery atherosclerosis, lacunar, and
cardiogenic embolism subgroups, respectively. No sta-
tistical difference was found between lacunar and
nonlacunar subgroups (P = .1266), between large artery
atherosclerosis subgroup and others (P = .0596), and
between cardiogenic embolism and noncardiogenic em-
bolism subgroups (P = .4420). Prevalence of responsiveness
to all antiplatelet medications within noncardiogenic sub-
groups overall and within the cardiogenic embolism
subgroup was 78.4% and 84.3%, respectively, without sta-
tistical differences (P = .2854).
Prevalence of Responsiveness in Clopidogrel Patients
according to CYP2C19 Genotype
Prevalence of responsiveness among the 130 Clopidogrel
patients of the study population, and separately in each
study group, according to the genetic polymorphism within
the CYP2C19 gene is shown in Table II in the online-
only Supplementary data. No significant difference was
found by Fisher exact testing (P = .5721). Particularly, no
difference was found in prevalence of Clopidogrel re-
sponsiveness between patients carrying the *2 allelic variant
(homozygous *2/*2 or heterozygous variants *2/*17, *1/
*2) and patients carrying other allelic variants in our 130
patients (P = .2715).
Discussion
In the present observational study, we assessed the prev-
alence of antiplatelet therapy responsiveness by using MEA
in a population of 624 patients with acute ischemic stroke.
Table 2. Association of unresponsiveness with demographic






OR P value OR P value
Gender (M versus F) .67 .0465 .73 .1555
Age 1.01 .1905 .99 .7132
Onset NIHSS 1.03 .0383 1.01 .5750
Discharge NIHSS 1.03 .0366 1.02 .3379
Hypertension 1.24 .3755 1.18 .5626
Previous stroke 1.06 .8299 .70 .2450
Previous TIA 1.31 .4220 .99 .9808
ICA stenosis >50% 1.30 .1972 1.03 .8874
Atrial fibrillation 1.04 .9011 .89 .7284
Diabetes mellitus 1.53 .0518 1.48 .1080
Prior myocardial
infarction
1.22 .4049 .91 .7467
Cigarette smoking .65 .0518 .71 .1723
Hyperlipidemia 1.17 .4837 1.17 .5331
Hyperhomocysteinemia 1.17 .4837 .99 .9759
History of neoplasia .96 .9035 1.13 .7604
Obesity 1.22 .4896 1.11 .7520
Foramen ovale patency .80 .6092 1.24 .6642
Clopidogrel versus ASA 2.89 <.0001 3.65 <.0001
ASA plus Clopidogrel
versus ASA




.80 .2720 .55 .0169
Abbreviations: ASA, aspirin; F, female; ICA, internal carotid artery;
M, male; NIHSS, National Institute of Health Stroke Scale; OR, odds
ratio; TIA, transient ischemic attack.
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Our findings showed that the prevalence of ASA respon-
siveness was significantly higher (P < .0010) in patients
who started antithrombotic therapy during hospitaliza-
tion (naive patients) compared with patients who were
already on antiplatelet prevention therapy with ASA at
the time of stroke onset (non-naive patients). As previ-
ously reported, the vascular event risk reduction in patients
taking ASA amounts to 22%, but the benefit in cerebro-
vascular patients, specifically, seems to be more modest.
Furthermore, it has been estimated that between 5% and
60% of patients on secondary prevention therapy with
ASA present a heterogeneous phenomenon known as
“aspirin resistance,”38 with possible associations between
aspirin resistance and repeated cerebrovascular isch-
emic events.39,40 The evidence that a consistent proportion
of patients on ASA, including patients with acute stroke
(as shown by the present study and by others7,38-40), are
“ASA-resistant,” raises the question as to whether
antiplatelet activity testing should be recommended in
patients with risk factors for ischemic stroke on ASA
because up to one third of subjects may be taking a bio-
logically ineffective medication. Multiple potential
mechanisms have been reported with regard to ASA re-
sistance, but poor therapeutic adherence and factors
affecting a faster platelet turnover (such as underlying
chronic inflammatory states depending on atherosclero-
sis or type 2 diabetes mellitus) are likely to contribute
to a good part of cases.38 In our study, the higher prev-
alence of ASA responsiveness (94.9%) observed in naive
patients might certainly be due to a global improve-
ment of therapeutic compliance, but it might be conceivable
that the tight control of concomitant cerebrovascular risk
factors, especially hyperglycemia or hyperlipidemia, in
these patients may account for the better response. Fur-
thermore, time-dependent changes in individual platelet
reactivity have been reported in patients with a previ-
ous ischemic stroke, with inconstant effects of a fixed dose
of ASA over time.41 Recently, other evidence showed an
independent association between the increase of plate-
let reactivity over time and early neurological deterioration
in patients with ischemic stroke.42,43
Logistic regression performed on the entire study pop-
ulation does not show any significant association between
patients’ demographic characteristics and comorbidities
and unresponsiveness to antiplatelet therapy; neverthe-
less, it revealed a strong effect of Clopidogrel therapy (alone
or in combination with ASA) as a “risk factor” for un-
responsiveness to antiplatelet therapy, regardless of the
duration of treatment, as this association is even more
significant if the variable “study group” is included in
the analysis. Our results, moreover, showed differences
in the responsiveness between antiplatelet medications
(ASA, Clopidogrel, or a combination of both drugs) in
the entire population and in the 2 subgroups: we found
a significantly better responsiveness to ASA therapy com-
pared with Clopidogrel or combination therapy in the
entire study population (P < .0010), both in non-naive pa-
tients (P < .0253) and in naive patients (P < .0010). Although
Figure 1. Graphic presentations of responsiveness to each tested antiplatelet therapy (ASA—black columns, Clopidogrel—dark gray columns, ASA plus
Clopidogrel—light gray columns) and related P values, in entire study population (A), in “non-naive patients” (B), and in “naive patients” (C).
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our results did not show any significant differences re-
garding Clopidogrel responsiveness between the study
groups (P = .2181), the proportion of Clopidogrel
nonresponders was higher than the proportion of ASA
nonresponders both in non-naive patients (27.3% versus
17.4%) and in naive patients (39.3% versus 5.1%). The
finding of a lower responsiveness to Clopidogrel therapy
in our stroke population is consistent with a wide variety
of previous studies.19,27,44 The phenomenon named
“Clopidogrel resistance,” highly variable in different popu-
lations (ranging from 15.9% to 49.5%),45 has been widely
reported in association with worse clinical outcomes in
patients with cardiovascular events. The cause of this phe-
nomenon is known to be multifactorial because it seems
to be dependent on several issues: choice of assay and
cutoff value,6 timing of testing, pharmacokinetic, drug–
drug interactions, comorbidities, age, genetic polymorphisms,
and poor compliance. We found similarities between the
prevalence of Clopidogrel resistance in our population
and other studies on patients with ischemic stroke tested
with MEA.27 We further hypothetically may assume that
the question of therapeutic adherence is less prominent
in patients treated with Clopidogrel than those in therapy
with ASA, as there were no significant differences between
study groups (non-naive patients and naive patients), and
the odds of being nonresponders is even higher if the
analysis is adjusted also for this factor. With regard to
the hypothesis that Clopidogrel nonresponsiveness in the
naive patients group might have been time-dependent,
this is not likely to have been an issue as mean testing
interval from stroke onset was 7-10 days, and evidence
has previously shown that the steady state of the Clopidogrel
antiplatelet effect is usually achieved in 3-5 days.46
Among patients who were already on prevention
antiplatelet therapy at baseline, we tried to assess the prev-
alence of responsiveness within etiological subgroups of
stroke to evaluate whether the information provided by
platelet function testing might help in the prediction of
the underlying stroke etiology. We found no significant
difference in responsiveness to all antiplatelet medica-
tions, Clopidogrel, and combination therapy between
etiological subgroups, whereas significant differences were
found considering ASA therapy (prevalence of ASA re-
sponsiveness was 90%, 74%, and 86% in large artery
atherosclerosis, lacunar, and cardiogenic embolism sub-
groups, respectively, P = .0479); this result, however, is
difficult to interpret. These findings were also reported
in a recent study in which ASA/Clopidogrel resistance
was not associated with a specific subgroup of stroke
mechanism.47 We noticed a higher prevalence of
nonresponsiveness to all medications, ASA, and combi-
nation of ASA and Clopidogrel (respectively 27%, 26%,
and 50%) in the small artery disease etiological sub-
group, but without statistical relevance. Greater ASA
resistance in lacunar strokes was reported in a previous
study,48 in which authors suggested that, rather than
anterior or posterior circulation strokes, which are often
caused by embolic mechanism in large vessels, in this
type of stroke, small arteries, already narrowed by in-
trinsic disease, might be more sensitive to the formation
of microthrombi due to lack of inhibition of platelet ac-
tivation induced by ASA. More recently, Cha et al reported
a significant correlation between large artery atheroscle-
rosis subtype of ischemic stroke and poor long-term
outcome in presence of HRPR after ADP stimuli.49
The main limit of the present study is its cross-
sectional design, which did not permit us to evaluate the
long-term outcome of patients with an inadequate inhi-
bition of platelet function, although data collection is
ongoing.
We finally evaluated the responsiveness among 130 pa-
tients of the study population on Clopidogrel therapy,
in which we assessed the CYP2C19 genotype. Notwith-
standing previous and recent reports of a higher prevalence
of unresponsiveness or adverse clinical events in pa-
tients carrying the LoF alleles,32,33 in our particular
population we did not find any statistical differences in
homozygous or heterozygous *2 allelic variants carriers.
One possible limitation of this result might be the small
size of our sample, because hypothetical “slow
metabolizers” (*2/*2 and *1/*2) were only 11. Converse-
ly, it might be hypothesized that in the Italian population,
other polymorphisms play a more significant role in
Clopidogrel pharmacokinetic than CYP2C19 alone. Other
clinical or biological factors rather than CYP2C19 poly-
morphisms could be related to the high prevalence of
unresponsiveness observed in the entire group of our
Clopidogrel patients. Further analyses on Clopidogrel
therapy and relevant functional genetic variants are needed.
Conclusion
The present observational study confirms that a sub-
stantial proportion of patients with acute stroke on ASA
showed biological resistance and that treatment with
Clopidogrel is accompanied by even higher rates of
nonresponsiveness. Monitoring the effect of antiplatelet
medications with platelet function testing in patients with
ischemic stroke could be potentially useful for prompt-
ly detecting any problems of poor compliance, which is
known to play a significant role in the phenomenon of
Aspirin resistance,50 in those patients who were already
on antiplatelet prevention therapy at the time of the stroke.
Furthermore, the possibility of testing the biological ef-
fectiveness of Clopidogrel in particular, which is widely
considered as equal to or even more effective than ASA,
although associated with higher rates of biological
nonresponsiveness, might supply helpful information to
clinicians because the therapeutic shift from 1 antiplatelet
agent to another is currently not supported by positive
evidence concerning the reduction of the risk of isch-
emic stroke recurrence.
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Longitudinal studies are needed to assess whether
aggregometry might supply individualized prognostic in-
formation and whether it can be considered a valid tool
in the development of tailored therapies in the future.
Appendix: Supplementary Material
Supplementary data to this article can be found online
at doi:10.1016/j.jstrokecerebrovasdis.2017.04.023.
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